Literature DB >> 187059

Use of vidarabine in epidemic keratoconjunctivitis due to adenovirus types 3, 7, 8, and 19.

E d Waring GO, P R Laibson, J E Satz, N H Joseph.   

Abstract

Adenovirus types 3,7,8, and 19 were isolated during an outbreak of epidemic keratoconjunctivitis. There was no clinically recognizable difference in the severity of the disease produced by each adenovirus type. Twenty-nine patients with positive viral cultures were given either 3.3% vidarabine ointment or polyvinyl alcohol eyedrops within five days of the onset od disease, and were observed for at least 14 days. An observer unaware of which medication was prescribed found subepithelial corneal infiltrates in 81% of vidarabine-treated patients and in 63% of control subjects. Vidarabine was ineffective in preventing subepithelial corneal infiltrates in keratoconjunctivitis caused by adenovirus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187059     DOI: 10.1016/0002-9394(76)90017-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Topical human fibroblast interferon for acute adenoviral conjunctivitis.

Authors:  K R Wilhelmus; E C Dunkel; J Herson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

Review 2.  Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment.

Authors:  Birthe Meyer-Rüsenberg; Ulrike Loderstädt; Gisbert Richard; Paul-Michael Kaulfers; Caroline Gesser
Journal:  Dtsch Arztebl Int       Date:  2011-07-08       Impact factor: 5.594

3.  Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.

Authors:  L Asena; E Şıngar Özdemir; A Burcu; E Ercan; M Çolak; D D Altınörs
Journal:  Eye (Lond)       Date:  2017-02-03       Impact factor: 3.775

Review 4.  Adenoviruses in the immunocompromised host.

Authors:  J C Hierholzer
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.